Quantum Biopharma Ltd (HUGE) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access HUGE Annual Income Statement →
This income statement overview for Quantum Biopharma Ltd spans from 0 to Sep 30 2025, showing how the company's revenues, expenses, and earnings have changed across reporting periods.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HUGE/income-statements
https://api.csimarket.com/api/v1/companies/HUGE/fundamentals
https://api.csimarket.com/api/v1/companies/HUGE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2025)
Q3 2025
(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) 0
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing0.00
Depreciation & Amortization0.15
Research and Development Expense0.00
Restructuring, Accretion & Impairment Charges0.00
Other Operating Expense / -Income0.00
Total operating costs including COS0.00
Operating income / -loss-4.68
Interest Income0.00
Net Interest (-)Expense / Income0.00
Other loss / -income0.00
Total costs & expenses0.00
Income & Taxes
Income / -loss before income taxes0.00
Income after income taxes0.00
Net income / -loss of other equity0.00
Income / -loss from continuing operations-4.75
Non-controlling interests0.57
Net income / -loss-4.75
Income / -loss to shareholder-0.57
EBIT0.00
EBITD0.00
EBITDA0.00
Earnings Per Share
Basic EPS (excl. extra items)-1.25
Basic Net EPS-1.25
Diluted Net EPS-1.25
4 historic quarters locked

Sign in to unlock the full Quantum Biopharma Ltd income statement history.

About HUGE Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI